Substance P receptor antagonists: a new antidepressive and anxiolytic mechanism?

被引：3

作者：

Lieb, K ^{[1
]}

Fiebich, BL ^{[1
]}

Berger, M ^{[1
]}

机构：

[1] Univ Klin Freiburg, Abt Psychiat & Psychotherapie, D-79104 Freiburg, Germany

来源：

NERVENARZT | 2000年 / 71卷 / 09期

关键词：

substance P; depressive disorder; anxiety disorders; neurokinin-1; receptors;

D O I：

10.1007/s001150050661

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Preclinical investigations suggest that the neuropeptide substance P might be involved in the etiopathology of pain, depression, and anxiety. In a recent study, the substance P receptor antagonist MK-869 showed antidepressant and anxiolytic activity in depressed outpatients which was comparable to a standard SSRI. The MK-869 was well tolerated. Although these findings are promising, further studies are necessary to prove the hypothesis that substance P receptor antagonists represent a new class of antidepressants or anxiolytics. Respective studies are currently underway.

引用

页码：758 / 761

页数：4

共 27 条

[1] An insertion/deletion polymorphism in the angiotensin converting enzyme gene is associated with both brain substance P contents and affective disorders [J].

Arinami, T ;

Li, LM ;

Mitsushio, H ;

Itokawa, M ;

Hamaguchi, H ;

Toru, M .

BIOLOGICAL PSYCHIATRY, 1996, 40 (11) :1122-1127

[2] CSF SUBSTANCE-P IMMUNOREACTIVITY IN AFFECTIVE-DISORDERS [J].

BERRETTINI, WH ;

RUBINOW, DR ;

NURNBERGER, JI ;

SIMMONSALLING, S ;

POST, RM ;

GERSHON, ES .

BIOLOGICAL PSYCHIATRY, 1985, 20 (09) :965-970

[3]

Block GA, 1998, NEUROLOGY, V50, pA225

[4] Substance P (NK1) receptors in the cingulate carter in unipolar and bipolar mood disorder and schizophrenia [J].

Burnet, PWJ ;

Harrison, PJ .

BIOLOGICAL PSYCHIATRY, 2000, 47 (01) :80-83

[5] Altered nociception, analgesia and aggression in mice lacking the receptor for substance P [J].

De Felipe, C ;

Herrero, JF ;

O'Brien, JA ;

Palmer, JA ;

Doyle, CA ;

Smith, AJH ;

Laird, JMA ;

Belmonte, C ;

Cervero, F ;

Hunt, SP .

NATURE, 1998, 392 (6674) :394-397

[6] BEHAVIORAL AND BIOCHEMICAL RESPONSES FOLLOWING ACTIVATION OF MIDBRAIN DOPAMINE PATHWAYS BY RECEPTOR SELECTIVE NEUROKININ AGONISTS [J].

ELLIOTT, PJ ;

MASON, GS ;

STEPHENSSMITH, M ;

HAGAN, RM .

NEUROPEPTIDES, 1991, 19 (02) :119-126

[7] MODULATION OF THE RAT MESOLIMBIC DOPAMINE PATHWAY BY NEUROKININS [J].

ELLIOTT, PJ ;

MASON, GS ;

GRAHAM, EA ;

TURPIN, MP ;

HAGAN, RM .

BEHAVIOURAL BRAIN RESEARCH, 1992, 51 (01) :77-82

[8] Can the placebo be the cure? [J].

Enserink, M .

SCIENCE, 1999, 284 (5412) :238-240

[9] Modulation of acetylcholine release in human cortical slices: Possible implications for Alzheimer's disease [J].

Feuerstein, TJ ;

Seeger, W .

PHARMACOLOGY & THERAPEUTICS, 1997, 74 (03) :333-347

[10] Anxiolytic action of a neurokinin(1) receptor antagonist in the social interaction test [J].

File, SE .

PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1997, 58 (03) :747-752

← 1 2 3 →